Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 18/20 | 0.80 |
| ▸ | LCK | P06239 | 6/20 | 0.80 |
| ▸ | SRC | P12931 | 4/20 | 0.80 |
| ▸ | TEK | Q02763 | 3/20 | 0.80 |
| ▸ | KDR | P35968 | 2/20 | 0.80 |
| ▸ | LYN | P07948 | 2/20 | 0.75 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.73 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.73 |
| ▸ | EGFR | P00533 | 3/20 | 0.64 |
| ▸ | ITK | Q08881 | 2/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.62 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.62 |
| ▸ | FYN | P06241 | 1/20 | 0.62 |
| ▸ | YES1 | P07947 | 1/20 | 0.62 |
| ▸ | HCK | P08631 | 1/20 | 0.62 |
| ▸ | FGR | P09769 | 1/20 | 0.62 |
| ▸ | FER | P16591 | 1/20 | 0.62 |
| ▸ | CSK | P41240 | 1/20 | 0.62 |
| ▸ | TEC | P42680 | 1/20 | 0.62 |
| ▸ | BLK | P51451 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6431013 | 1.00 | BTK (0.80) | BTKLCKSRCTEKKDR | |
| SCHEMBL5804172 | 1.00 | BTK (0.80) | BTKLCKSRCTEKKDR | |
| SCHEMBL30144776 | 0.94 | BTK (0.75) | BTKLCKSRCTEKKDR | |
| SCHEMBL6435508 | 0.94 | BTK (0.75) | BTKLCKSRCTEKKDR | |
| SCHEMBL22720882 | 0.94 | BTK (0.75) | BTKLCKSRCTEKKDR | |
| SCHEMBL22737441 | 0.94 | BTK (0.75) | BTKLCKSRCTEKKDR | |
| SCHEMBL22720857 | 0.94 | BTK (0.75) | BTKLCKSRCTEKKDR | |
| Trifluoroacetic Acid SCHEMBL28932027 | 0.93 | BTK (0.70) | BTKLCKSRCTEKKDR | |
| SCHEMBL30301973 | 0.93 | BTK (0.77) | BTKLCKSRCTEKKDR | |
| SCHEMBL26105120 | 0.92 | BTK (0.81) | BTKLCKSRCTEKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564591-B2 | HCK as a therapeutic target in MYD88 mutated diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4041239-B1 | A PYRRAZOLOPYRIMIDINE DERIVATIVE AS A HCK INHIBITOR FOR USE IN THERAPY, IN PARTICULAR MYD88 MUTATED DISEASES | DANA FARBER CANCER INST INC (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025137500-A1 | KINASE INHIBITION AND DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-114746095-B | HCK as therapeutic target of MYD88 mutant diseases | 达纳-法伯癌症研究所有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-118201929-A | PROTAC compound, pharmaceutical composition containing same, and preparation method and application thereof | 广东弘烨医药科技有限公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023072270-A1 | PROTAC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | 百极弘烨(南通)医药科技有限公司 | 2023-05-04 | — | — | WO | disclosed |
| WO-2023072270-A1 | PROTAC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | 百极弘烨(南通)医药科技有限公司 | 2023-05-04 | — | — | WO | disclosed |
| US-20220395509-A1 | A PYRAZOLOPYRIMIDINE DERIVATIVE AS A HCK INHIBITOR FOR USE IN THERAPY, IN PARTICULAR MYD88 MUTATED DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| EP-4041239-A1 | A PYRAZOLOPYRIMIDINE DERIVATIVE AS A HCK INHIBITOR FOR USE IN THERAPY, IN PARTICULAR MYD88 MUTATED DISEASES | Dana-Farber Cancer Institute, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114746095-A | HCK as therapeutic target of MYD88 mutant disease | 达纳-法伯癌症研究所有限公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| WO-2004100868-A2 | METHOD OF TREATING TRANSPLANT REJECTION | ABBOTT LABORATORIES (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-1212327-B8 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2004-02-25 | — | — | EP | disclosed |
| EP-1385524-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | Abbott GmbH & Co. KG (DE) | 2004-02-04 | — | — | EP | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
| EP-1212327-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019829-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | BTK 42/4885LCK 1/4885SRC 46/4885 |
| US-20220395509-A1 | A PYRAZOLOPYRIMIDINE DERIVATIVE AS A HCK INHIBITOR FOR USE IN THERAPY, IN PARTICULAR MYD88 MUTATED DISEASES | HCK, BTK, MYD88 | BTK 2/4885LCK 15/4885SRC 47/4885 |
| US-12564591-B2 | HCK as a therapeutic target in MYD88 mutated diseases | HCK, BTK, LYN | BTK 2/4885LCK 22/4885SRC 7/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | BTK 1020/4885LCK 1011/4885SRC 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.